| Project/Area Number |
22591160
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OKA Yoshihiro 大阪大学, 大学院・医学絵系研究科, 講師 (20273691)
OHTA Hideaki 大阪大学, 大学院・医学絵系研究科, 講師 (60322187)
MIYASHITA Emiko 大阪大学, 大学院・医学絵系研究科, 助教 (40528395)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 小児腫瘍学 / 癌ワクチン / 免疫療法 / 同種造血幹細胞移植 / 小児血液悪性腫瘍 / WT1ペプチドワクチン |
|---|
| Research Abstract |
Wilms tumor gene, WT1, is highly expressed in hematological malignancy. The gene product (WT1 protein) could be a good target antigen for immunotherapy against leukemia. We started the clinical trial of WT1 peptide vaccination after stem cell transplantation with high risk hematological malignancy from 2010. 18 pediatric patients had been enrolled and 13 patients maintained complete remission. The number of WT1 specific cytotoxic T lymphocytes were increased in these patientswith remission. Our results highlight the potential of WT1 vaccination to boost the GVL effect.
|
